Simulations Plus Inc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SLP | CERT | 2228.HK | BFRG | VIVOBIOT.BO | GENB | |
|---|---|---|---|---|---|---|
| Market cap | — | 1.69B | 27.39B | 9.76M | 328.87M | 1.82B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | 28.3 | 170.6 | -3.1 | — | -6.2 |
| Price/book | — | 1.7 | 2.6 | 1.4 | 0.3 | 4.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | — | −6.05% | −43.12% | −50.19% | −58.81% | +9.49% |
| Today | 0.00% | +2.02% | +4.17% | +0.59% | +6.77% | +2.24% |
The closest companies by business and industry (Health Information Services). Prices may be delayed up to 15 min.
Latest news
All SLP news ›Analyzing Simulations Plus (NASDAQ:SLP) and Revvity (NYSE:RVTY)
Posted by Kim Johansen on Oct 27th, 2026 Simulations Plus (NASDAQ:SLP – Get Free Report) and Revvity (NYSE:RVTY – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on…
[15-12G] Simulations Plus, Inc. SEC Filing
Simulations Plus, Inc. SEC Filing (Oct 16, 2026) Stock Titan [15-12G] Simulations Plus, Inc. SEC Filing Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a…
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
Supply Chain Digital Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures SAN DIEGO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is inv
Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin
BioSpace Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin Collaboration will
Simulations Plus: DiBella disposes of 85,140 shares
Simulations Plus, Inc. (Nasdaq: SLP) offers biosimulation software, ADMET tools, and consulting services that support model-informed, AI-accelerated drug development. - [Form 4] Simulations Plus, Inc. Insider Trading Activity Simulations…
Simulations Plus director Evans disposes of 17,173 shares
Simulations Plus, Inc. (Nasdaq: SLP) offers biosimulation software, ADMET tools, and consulting services that support model-informed, AI-accelerated drug development. - [Form 4] Simulations Plus, Inc. Insider Trading Activity Simulations…
Sharlene Evans Sells 17,173 Shares of Simulations Plus in $18.50 Per Share Merger Deal
Kalkine Media On October 6, 2026, Director Sharlene Evans submitted a Form 4 to the SEC disclosing the sale of 17,173 shares of Simulations Plus, Inc. common stock related to the company's merger, with each share
Simulations Plus appoints Paul Labute as President; Matteo Foderaro and Charles Mullens join board
TradingView Simulations Plus appoints Paul Labute as President; Matteo Foderaro and Charles Mullens join board Simulations Plus appointed Paul Labute as President following the consummation of the mer
Simulations Plus director disposes of 16,547 shares
Simulations Plus, Inc. (Nasdaq: SLP) offers biosimulation software, ADMET tools, and consulting services that support model-informed, AI-accelerated drug development. - [Form 4] Simulations Plus, Inc. Insider Trading Activity Simulations…
Simulations Plus insiders dispose of 3.2M merger shares
Simulations Plus, Inc. (Nasdaq: SLP) offers biosimulation software, ADMET tools, and consulting services that support model-informed, AI-accelerated drug development. - [Form 4] Simulations Plus, Inc. Insider Trading Activity Simulations…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net15
- biospace.com1
- globenewswire.com1
- kalkinemedia.com1
- scanx.trade1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 22 articles, not a forecast.